Get the Stockscreener App
2.51
1.18%
-0.03
After Hours:
2.50
-0.010
-0.40%
Tharimmune Inc stock is traded at $2.51, with a volume of 99,306.
It is down -1.18% in the last 24 hours and down -18.77% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$2.54
Open:
$2.45
24h Volume:
99,306
Relative Volume:
0.03
Market Cap:
$87.96M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.1975
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
-4.92%
1M Performance:
-18.77%
6M Performance:
+84.89%
1Y Performance:
+2.45%
1-Day Range:
$2.41
$2.54
1-Week Range:
$2.1805
$2.72
52-Week Range:
$0.952
$9.08
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
2.51 | 89.01M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tharimmune Inc Stock (THAR) Latest News
Crypto Company Creates Bizarre Drug - Futurism
Tharimmune Stock Plummets -46% With 9-Day Losing Streak - Trefis
Using Bollinger Bands to evaluate Tharimmune Inc.Gap Up & Expert Curated Trade Setups - newser.com
Will Tharimmune Inc. stock benefit from sector rotationPortfolio Performance Report & Free Accurate Trade Setup Notifications - newser.com
Why analysts upgrade Tharimmune Inc. stockJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
How resilient is Tharimmune Inc. stock in market downturnsWatch List & Trade Opportunity Analysis Reports - newser.com
Is Tharimmune Inc. stock a buy for dividend growthTrade Exit Summary & Stepwise Swing Trade Plans - newser.com
What insider trading reveals about Tharimmune Inc. stock2025 Momentum Check & Safe Capital Growth Tips - newser.com
Is Tharimmune Inc. stock attractive for retirement portfoliosWeekly Gains Report & Capital Efficiency Focused Strategies - newser.com
Will Tharimmune Inc. stock deliver long term returnsInsider Selling & Verified Momentum Stock Alerts - newser.com
What the charts say about Tharimmune Inc. todayMarket Risk Report & Pattern Based Trade Signal System - newser.com
Will earnings trigger a reversal in Tharimmune Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
Using data models to predict Tharimmune Inc. stock movementWeekly Investment Summary & Accurate Buy Signal Alerts - newser.com
Will Tharimmune Inc. stock sustain high P E ratiosWall Street Watch & High Accuracy Swing Entry Alerts - newser.com
Is Tharimmune Inc. still worth holding after the dip2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
Tharimmune Shares Jump After FDA Signals Support for TH104 Modeling Plan - MSN
Tharimmune Shares Drop Premarket Following FDA Feedback on Plan for Lead Clinical Asset - MarketScreener
Tharimmune rises after US FDA backs opioid overdose prevention drug plan - TradingView
Tharimmune stock rises after FDA provides positive feedback on TH104 By Investing.com - Investing.com Nigeria
Tharimmune stock rises after FDA provides positive feedback on TH104 - Investing.com
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids - Stock Titan
Tharimmune appoints Sireesh Appajosyula as interim CFO through year-end - Investing.com
Tharimmune appoints Sireesh Appajosyula as interim CFO through year-end By Investing.com - Investing.com UK
Tharimmune appoints Sireesh Appajosyula as interim CFO on Nov 7SEC filing - MarketScreener
Tharimmune Closes $545M Private Placement for Blockchain Strategy - The Globe and Mail
Tharimmune makes a pivot into digital assets, raises approximately $540 million via a private placement - MSN
Tharimmune entered ATM sales agreement worth up to $64.9 millionSEC filing - MarketScreener
Tharimmune closes $545 million private placement for Canton Coin strategy By Investing.com - Investing.com Australia
Tharimmune: $545 Million Private Placement Closed To Advance Canton Coin Treasury Strategy - Pulse 2.0
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):